Rarity Bioscience

Rarity Bioscience is a Stockholm-based diagnostics company commercializing its proprietary superRCA® technology, an ultrasensitive, multiplex molecular amplification platform. The technology detects mutations at a sensitivity of 1 in 100,000, significantly outperforming standard methods, and utilizes flow cytometry for a fast, cost-efficient readout. Founded in 2021, the company has established a U.S. subsidiary and secured a key validation partnership with ARUP Laboratories, positioning it to capture market share in the growing liquid biopsy space. Its focus is on providing research assays, service testing, and custom kits to enable more accessible and sensitive cancer mutation detection.

superRCA® (super Rolling Circle Amplification): An ultrasensitive, isothermal, multiplex nucleic acid amplification technology using padlock probes and flow cytometry readout to detect rare DNA mutations with a sensitivity of 1:100,000.

Rarity competes in the high-sensitivity molecular diagnostics space against companies using digital PCR (e.g., Bio-Rad, Qiagen) and next-generation sequencing (e.g., Guardant Health, Foundation Medicine). Its key differentiator is combining ultra-high sensitivity (1:100,000) with high multiplexing capability in a workflow that uses standard flow cytometry, potentially offering a cost and throughput advantage over dPCR for multiplexed applications.